Skip to main content
. Author manuscript; available in PMC: 2014 Oct 7.
Published in final edited form as: Med Res Rev. 2011 Jun 14;33(1):54–111. doi: 10.1002/med.20245

Table II.

Development of PET and SPECT Radioligands for the 5-HT System Designed for Use in Human Subjects

Target Type Radioligand Rodent Nonhuman primate Human Ongoing studies Reason for failure Known problems
5-HT1A SPECT [123I]p-MPPI × No specific 5-HT1A binding Rapid metabolism Possible brain exclusion via efflux transporter
PET [11C]WAY-100635 Fast systemic metabolism; difficult kinetic modelling with arterial input function, reference tissue models complicated by radiometabolites in plasma
[11C]CPC-222 ND ND Lower signal-to-background ratio than [11C]WAY-100635
[11C](R)-RWAY × × Possible influx of lipophilic radiometabolite P-gp substrate in rodent
[11C]DWAY ND Unreliable radiolabelling technique; low radioactive yield
[18F]6FPWAY ND × Moderate uptake
[18F]MPPF P-gp substrate; fast brain clearance and low uptake
[18F]FCWAY Defluorination of parent compound; sub-optimal imaging
[18F]MefWAY ND ND
[11C]NAD-299 ND ND
[11C]CUMI-101 Partial, not full agonist
5-HT1B PET [11C]AZ10419369 ND
[11C]P943 ND
5-HT2A SPECT [123I]DOI × × Low target-to-background ratio Non-selective (5-HT2C)
[123I]MSP ND ND ND
[123I]-R91150 Lower target-to-background ratio than equivalent PET tracers
[123I]-3-I-CO × ND Low target-to-background ratio, possible P-gp substrate
PET [11C]Ketanserin ND ND × Low target-to-background ratio, fast metabolism Non-selective (α1, H1, 5-HT2C)
[11C]NMSP ND ND Non-selective (D2)
[11C]MBL ND Non-selective (some D2, α1, 5-HT1 and 5-HT2C)
[18F]setoperone Non-selective (D2)
[18F]altanserin Need for bolus-infusion due to radiometabolites requiring complex modelling using other methods. Possible mixed pharmacology
[18F]deuteroaltanserin ND
[18F]RP62203 ND Multi-step radiosynthesis
[11C]MDL100907 Arterial input function needed
[18F]MH.MZ × ND ND Extensive first-pass metabolism, slow washout -
(R)-[18F]MH.MZ ND ND
[11C]Cimbi-5 and 36 ✔ (pig) ND ND
5-HT3 PET [11C]MDL 72222 × × Lack of specific binding, high lipophilicity Low 5-HT3 brain density
[11C]YM060, [11C]Y-25130 × Low brain uptake, low lipophilicity, ionisation of tertiary amide
[11C]KF17643 × No specific binding
[11C]S21007 × × No specific binding
[18F]MR18445 × × No specific binding
[11C]NMQ × × Rapid kinetics, high non-specific binding
5-HT4 SPECT [123I]SB207710 × ND
PET [11C]SB207145 ✔ (pig) Slow kinetics
5-HT6 PET [18F]12ST05 × No specific binding
[11C]GSK215083 ND ✔ (pig)
[11C]GSK224558 ND (pig only) ND Inferior ligand compared with [11C]GSK215083
5-HT7 PET [11C]DR4446 ND × Minimal specific binding
SERT SPECT β-[123I]CIT, nor-β-[123I]CIT Non-selective (DAT, NET)
[123I]ADAM Lower resolution than equivalent PET tracers. Ratio method of quantification over-estimates specific binding
PET [11C]McN5652 Slow brain uptake, irreversible kinetics complicate quantification
[11C]DASB
[11C]MADAM ND
[18F]ADAM ND
5-HT synthesis [11C]-AMT Low target-to-background ratio, analysis complicated by possible blood-brain barrier exchange and additional metabolic pathways
[11C]-HTP Lack of correlation with [11C]-AMT in direct comparison suggests further validation is necessary

✔ indicates that ex vivo, PET, or SPECT studies were performed and the ligand was considered successful in the species identified. In certain instances, radioligands were tested in pig brain either in addition to, or instead of nonhuman primate. × indicates that ex vivo, PET, or SPECT studies were performed but the ligand was not considered successful in the species indicated. “Ongoing studies” indicate that the ligand is still being used for research or clinical purposes in humans. ND indicates not yet determined, i.e. experiments have not been published in the species indicated. Missing data are either not applicable (−) or not available/not known (blank cells).